Piper Sandler analyst Christopher Raymond says he continues to believe shares of Aimmune Therapeutics can trade into the $60 range following Friday's FDA approval of peanut allergy treatment Palforzia. The stock in premarket trading is up 22%, or $6.95, to $38.00. The approval comes with little surprise in the way of labeling, pricing and approach to launch, Raymond tells investors in a research note. He believes there is "massive demand" and that Aimmune has done an "excellent job of preparing the market for this pioneering therapy." The analyst is buyer of the shares on today's open and says Aimmune remains a favorite name for 2020. Raymond keeps an Overweight rating on the shares with a $60 price target.